...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biomaterials >Transdermal regulation of vascular network bioengineering using a photopolymerizable methacrylated gelatin hydrogel
【24h】

Transdermal regulation of vascular network bioengineering using a photopolymerizable methacrylated gelatin hydrogel

机译：使用可光聚合的甲基丙烯酸明胶水凝胶进行血管网生物工程的透皮调控

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The discovery of highly proliferative endothelial colony-forming cells (ECFCs) in human peripheral blood [1,2] and in the vessel wall of some blood vessels [3] has created a promising opportunity to obtain large quantities of readily available endothelial cells (ECs) for autologous vascular therapies. Indeed, multiple studies have shown that ECFCs have a robust vasculogenic potential that can be exploited to generate long-lasting, stable vascular networks in vivo [4e7]. A critical requirement for bioengineering vascular networks is the use of a suitable biomaterial that can serve as a scaffold for the cells. Over the last few years, a variety of natural hydrogel biomaterials have been shown to be compatible with ECFC-mediated vascular morphogenesis, including Matrigel [4,8], type-I collagen [5,9,10], and fibrin gels [7,11], which indicates the versatility of ECFCs with regards to natural hydrogels in vivo. However, the properties of these materials are not always ideal for tissue engineering applications. For instance, Matrigel is not suitable for clinical use because it is derived from murine tumors [12]. Fibrin hydrogels have limitations such as poor mechanical stability or suboptimal durability [13]. Collagen hydrogels also have limitations in terms of extensive contraction, poor mechanical properties, and rapid degradation [14], all of which provide challenges towards their utilization as permanent graft material. Moreover, full polymerization of most collagen formulations at body temperature does not occur immediately, which may compromise gel-cell confinement if implanted in highly mobile tissues such as skeletal muscles or myocardium.
机译：在人周围血液[1,2]和一些血管的血管壁中发现高增殖的内皮菌落形成细胞（ECFC）[3]创造了获得大量容易获得的内皮细胞（ECS ）用于自体血管疗法。实际上，多项研究表明，ECFC具有强大的血管性潜力，可以利用在体内产生长期稳定的血管网络[4E7]。对生物工程血管网络的关键要求是使用合适的生物材料，其可以用作细胞支架。在过去几年中，已经显示出各种天然水凝胶生物材料与ECFC介导的血管形态发生相容，包括Matrigel [4,8]，I型胶原蛋白[5,9,10]和纤维蛋白凝胶[7 11]这表明ECFC在体内天然水凝胶方面的多功能性。然而，这些材料的性质并不总是适用于组织工程应用。例如，Matrigel不适合临床使用，因为它衍生自鼠肿瘤[12]。纤维蛋白水凝胶具有诸如机械稳定性差或次优耐久性的限制[13]。胶原蛋白水凝胶在广泛的收缩，机械性能差和快速降解方面也具有限制[14]，所有这些都为其作为永久接枝材料提供了挑战。此外，在体温下的大多数胶原制剂的完全聚合不会立即发生，这可能会在植入诸如骨骼肌或心肌等高度流动组织中植入的凝胶细胞限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号